NASDAQ · Biotechnology

SNGX (SNGX) Stock

$0.37 -0.29% NASDAQ: SNGX Healthcare

Valuation

MetricValue
Price$0.37
Market Cap$5.54M
P/E Ratio-0.18
P/B Ratio0.80
P/S Ratio0.00
EPS (TTM)$-2.14
52-Week High$6.23
52-Week Low$0.28
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-220.00%
ROA-122.22%
ROCE-240.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.11
Current Ratio2.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-13.0M$-14.0M$-8.0M$-9.0M$-12.0M
Net Profit$-13.0M$-14.0M$-6.0M$-8.0M$-11.0M
EPS$-75.06$-76.89$-12.66$-4.98$-2.14
Op Margin-39276.1%-5695.6%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$27.0M$14.0M$10.0M$9.0M$9.0M
Total Liabilities$16.0M$17.0M$7.0M$5.0M$4.0M
Cash$26.0M$13.0M$8.0M$8.0M$8.0M
Borrowings$10.0M$10.0M$3.0M$1.0M$0

Latest News

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine PR Newswire · Jun 8, 2026 BC-Most Active Stocks Associated Press · May 27, 2026 SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy Stocktwits · May 27, 2026 Top Premarket Gainers MT Newswires · May 27, 2026 Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo PR Newswire · May 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$-13.0M$-9.0M$-8.0M$-10.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$-1.0M$0$-1.0M$3.0M$-1.0M
Net Cash Flow$7.0M$-13.0M$-5.0M$-1.0M$0
Free Cash Flow$-12.0M$-13.0M$-9.0M$-8.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-268.12%
Quick Ratio1.81
Interest Coverage—
Return 1Y-70.24%
Return 3Y-96.63%
Return 5Y-99.84%

Ownership

Insiders Held6.74%
Institutions Held5.33%
Institutions Float Held5.72%
Institutional HolderSharesReport Date
Geode Capital Management, LLC120,2672026-03-31
Vanguard Capital Management LLC58,4002026-03-31
Vanguard Fiduciary Trust Co53,9142026-03-31
Xtx Topco Ltd20,7992026-03-31
UBS Group AG2,3462026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CANFCan-Fite BioPharma Ltd. $3.30 -2.37% -0.74 $1.78M 0.00%
CMND $1.62 +0.52% -0.79 $2.41M 0.00%
ENSCEnsysce Biosciences, Inc. $0.26 -1.95% -0.08 $2.38M 0.00%
KZIAKazia Therapeutics Ltd ADR $14.54 +2.76% -2.01 $23.55M 0.00%
OGEN $0.50 -1.96% -0.14 $2.26M 0.00%

About SNGX

SNGX is led by CEO Christopher J. Schaber, employs 14 people, headquartered in US, publicly traded since 1994.

SNGX stock trades at $0.37 with a market capitalization of $5.54M. The stock is valued at a price-to-earnings (P/E) ratio of -0.18, price-to-book of 0.80, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.28 and $6.23, and currently trades 94.1% below its 52-week high.

On profitability, SNGX generates a return on equity (ROE) of -220.00%, return on capital employed of -240.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides